Supplemental material
Scandinavian Journal of Gastroenterology
Volume 57, 2022 - Issue 7
Original Articles
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn’s disease: an analysis of two propensity score-matched cohorts
M. Lukasa IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republic;b First Medical Faculty, Charles University, Prague, Czech RepublicCorrespondence[email protected]
https://orcid.org/0000-0002-1463-3840View further author information
https://orcid.org/0000-0002-1463-3840View further author information, M. Kolara IBD Clinical and Research Centre, ISCARE a.s., Prague, Czech Republichttps://orcid.org/0000-0001-9501-0604View further author information
https://orcid.org/0000-0001-9501-0604View further author information, , , , , , , , & show allRelated Research Data
A switch from originator-adalimumab to the biosimilar SB5 in patients with Crohn���s disease: an analysis of two propensity score-matched cohorts
Source:
Taylor & Francis
Linking provided by
